
发布时间:2026-11-19T03:37:45+08:00 加州最大的健康保险公司之一希望改变其覆盖GLP-1类药物的方式,将其支付的费用与药物疗效挂钩,以试图降低患者支出。
Published: 2026-11-19T03:37:45+08:00 One of California’s largest health insurers wants to change the way it covers GLP-1 drugs, tying the cost it will pay to how well the medicines work in an attempt to lower patient spending.
“我非常希望我们能转向类似订阅加奖金的模式,”Ascendiun首席执行官、Blue Shield of California母公司掌舵人Paul Markovich在彭博纽约办公室接受采访时表示。该保险公司将按月向药企支付费用,使其所有会员在需要时都能获得这些药物,随后若患者实现积极疗效——如降低血糖或体重——再支付额外费用。
“I would love to see us move to something like a subscription and bonus model,” Paul Markovich, chief executive officer of Ascendiun, the parent company of Blue Shield of California, said in an interview at Bloomberg’s New York offices. The insurer would pay a monthly fee to drugmakers for all of its members to get access to the drugs when they’re needed, and then pay extra if the patients achieve positive outcomes, such lowering their blood sugar or weight.
Markovich表示,减重畅销药Zepbound的制造商礼来公司,以及Wegovy的制造商诺和诺德,均知晓其公司的这一意向。两家公司均未立即回应置评请求。
Markovich said that Eli Lilly & Co., maker of weight-loss blockbuster Zepbound, and Novo Nordisk A/S, which manufactures Wegovy, are both aware of his company’s interest. Neither company immediately responded to requests for comment.
GLP-1类药物使用量上升推高了健康保险保费,导致健康计划不愿覆盖此类药物用于治疗肥胖。据咨询公司Willis Towers Watson PLC的一项调查,今年雇主覆盖GLP-1类药物用于减重的比例从56%下降至53%。
Rising GLP-1 use has contributed to increasing health insurance premiums, making health plans reluctant to cover the medicines for obesity. The share of employers covering GLP-1s for weight loss dropped from 56% to 53% this year, according to a survey by the consulting firm Willis Towers Watson PLC.
Markovich预计,订阅加奖金模式“可能会大幅降低患者成本”。细节仍在敲定中,他表示可能需要调整法规才能使此类协议生效。
Markovich said he expects the subscription-and-bonus model would “reduce patient costs possibly substantially.”The details are still being worked out, and he said that regulations may need to be adjusted to make such deals work.
根据药物疗效付费的构想在医疗行业已酝酿多年,被视为降低成本的一种途径,尤其是针对基因疗法等高成本治疗,但鲜有实质进展。
Paying for drugs based on how well they work is an idea that’s been floated for years in the healthcare industry as a way to lower costs, particularly for high-cost treatments like gene therapies, but it’s seen little traction.
同样,健康计划也在探索针对包括GLP-1类药物在内的药品采用订阅制模式,但鲜有采纳。根据临床与经济评价研究所2025年的一份报告,一些大型采购方曾考虑过此类安排,但未获得多少兴趣。
Similarly, health plans have been looking at subscription-style models for medicines including GLP-1s, with little uptake. Some large purchasers have considered arrangements like this, but didn’t receive much interest, according to a 2025 report by the Institute for Clinical and Economic Review.
这一举措是马科维奇三年前宣布的、旨在通过直接与药企谈判药价来降低医疗成本的尝试的一部分。该公司不再仅使用 CVS Health Corp. 作为其药福利管理公司,而是引入其他公司,试图每年节省 5 亿美元。
The effort is part of Markovich’s attempt to reduce healthcare costs by directly negotiating drug prices with manufacturers, which he announced three years ago. The company stopped using CVS Health Corp. as its sole pharmacy benefit manager, brining in other companies in an attempt to save $500 million annually.
马科维奇表示,目前公司每年已节省 1.5 亿美元。蓝盾加州已降低了管理成本,并在纠正医疗服务提供者错位的财务激励方面取得进展。但直接与药企谈判价格比他预想的要难。
Markovich said that the company has saved $150 million annually so far. Blue Shield of California has reduced administrative costs and is making progress fixing healthcare providers’ misaligned financial incentives. But negotiating prices directly with drug companies has been harder than he thought it would be.
“我们并没有真正取得突破,”马科维奇说。他表示,公司目前仅就不到 10 种药品与药企达成了直接定价协议。
“We have not really broken through,” Markovich said. The company has deals with drug companies on direct pricing for fewer than 10 medicines, he said.